Last $8.27 USD
Change Today -0.26 / -3.05%
Volume 678.0K
AFFX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFFX) Snapshot

Open
$8.56
Previous Close
$8.53
Day High
$8.56
Day Low
$8.13
52 Week High
01/21/14 - $9.80
52 Week Low
09/24/13 - $5.90
Market Cap
606.9M
Average Volume 10 Days
402.8K
EPS TTM
$-0.12
Shares Outstanding
73.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMETRIX INC (AFFX)

affymetrix inc (AFFX) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFFX) Details

Affymetrix, Inc. provides life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment is engaged in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line, such as the Axiom product line; arrays and assays with clinical research applications, such as the CytoScan and OncoScan products; QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets; and GeneTitan family of products consisting of the GeneTitan instrument system that runs genotyping and gene expression array plates. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta assay portfolio. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

1,100 Employees
Last Reported Date: 08/4/14
Founded in 1991

affymetrix inc (AFFX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $498.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $281.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $376.5K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2013.

affymetrix inc (AFFX) Key Developments

Affymetrix Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Raises Financial Guidance for the Full Year of 2014

Affymetrix Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $85,432,000 against $79,464,000 a year ago. Loss from operations was $304,000 against $2,951,000 a year ago. Loss before income taxes was $509,000 against $5,586,000 a year ago. Net loss was $911,000 or $0.01 basic and diluted per share against $6,107,000 or $0.09 basic and diluted per share a year ago. Non-GAAP net income was $5,157,000 or $0.07 basic and diluted per share against $2,786,000 or $0.04 basic and diluted per share a year ago. EBITDAO was $13,864,000 against $13,648,000 a year ago. Total second quarter revenue increased by $6 million or approximately 7.5%, primarily due to strength in the Genetic Analysis business unit. The capital expenditure during the second quarter was approximately $1.9 million. For the six months, the company reported total revenue of $168,403,000 against $157,409,000 a year ago. Loss from operations was $9,045,000 against $15,157,000 a year ago. Loss before income taxes was $10,711,000 against $20,347,000 a year ago. Net loss was $11,385,000 or $0.16 basic and diluted per share against $21,543,000 or $0.30 basic and diluted per share a year ago. Non-GAAP net income was $7,061,000 or $0.10 basic and diluted per share against $1,931,000 or $0.03 basic and diluted per share a year ago. EBITDAO was $26,780,000 against $24,296,000 a year ago. Based on the year-to-date performance and improved visibility in the balance of the year, the company is raising its full year guidance to total revenue of $340 million and EBITDA in the range of 14% to 15%.

Affymetrix Inc. to Report Q2, 2014 Results on Jul 31, 2014

Affymetrix Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

Affymetrix Inc., Q2 2014 Earnings Call, Jul 31, 2014

Affymetrix Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFFX:US $8.27 USD -0.26

AFFX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abcam PLC 418.50 GBp +4.00
Enzo Biochem Inc $5.32 USD -0.32
Fluidigm Corp $26.33 USD -1.77
Luminex Corp $19.21 USD -0.72
Pacific Biosciences of California Inc $5.01 USD -0.14
View Industry Companies
 

Industry Analysis

AFFX

Industry Average

Valuation AFFX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.